

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Lisdexamfetamine (Vyvanse)

Notes:

- ^ Adequate trial of a long-acting agent is further defined as wearing off that is not resolved by increasing the dose, AND adding a short-acting agent OR increasing frequency to twice daily OR clinically significant side effects related to the dosage form that cannot be resolved by adjusting the dose or timing.
- **Adequate trial of a short acting agent is further defined as wearing off that is not resolved by increasing the dose and the frequency to a minimum of twice daily OR clinically significant side effects related to the short-acting dosage form that cannot be resolved by adjusting the dose or timing.
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Initiation (new start) criteria: Non-formulary **lisdexamfetamine (Vyvanse)** will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD)
 - Patient has failed an adequate trial ^ of a long-acting amphetamine product (Adderall XR, etc), unless allergy to an inactive ingredient
 - Patient has failed an adequate trial ^ of a long-acting dextroamphetamine ER (Dexedrine Spansule), unless allergy to an inactive ingredient
 - Patient has failed an adequate trial^ of a methylphenidate ER (Concerta, Metadate CD, Ritalin LA) or dexmethylphenidate ER (Focalin XR), unless allergy to an inactive ingredient
- OR -**
- Diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD) and past diagnosis or treatment for substance use disorder

Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-formulary **lisdexamfetamine (Vyvanse)** will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD)
- Patient has failed an adequate trial ^ of a long-acting amphetamine product (Adderall XR, etc), unless allergy to an inactive ingredient
- Patient has failed an adequate trial ^ of a long-acting dextroamphetamine ER (Dexedrine Spansule), unless allergy to an inactive ingredient
- Patient has failed an adequate trial^ of a methylphenidate ER (Concerta, Metadate CD, Ritalin LA) or dexmethylphenidate ER (Focalin XR), unless allergy to an inactive ingredient

kp.org

Revised: 06/12/2025
Effective: 08/07/2025

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Lisdexamfetamine (Vyvanse)

- OR -

- Diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD) and past diagnosis or treatment for substance use disorder

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary **lisdexamfetamine (Vyvanse)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient is over 21 year of age
- Diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD)
- Patient has failed an adequate trial ^ of a long-acting amphetamine product (Adderall XR, etc), unless allergy to an inactive ingredient
- Patient has failed an adequate trial ^ of a long-acting dextroamphetamine ER (Dexedrine Spansule), unless allergy to an inactive ingredient

- OR -

- Diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD) and past diagnosis or treatment for substance use disorder

- OR -

- Diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD) and patient is age 6 to 20 years old and stable on medication

Non-formulary **lisdexamfetamine (Vyvanse)** will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of Binge Eating Disorder
- Prior adequate trial (6 weeks) and failure of 2 formulary Selective Serotonin Reuptake Inhibitors (SSRIs) unless contraindication, intolerance, or allergy
- Adequate trial** (7 days) of dextroamphetamine ER (Dexedrine Spansules), unless allergy to an inactive ingredient or history of substance use disorder

- OR -

- Patient is already stable on drug